Abstract
An in vivo effect of a novel synthetic Xa inhibitor, DX-9065a, was evaluated in a highly thrombogenic venous graft model. A woven Tetron tube graft was interposed in the inferior vena cava of rabbits. All the grafts were completely occluded within 5 hours after a bolus injection of heparin (50 U/kg) given just prior to the grafting. The following agents were continuously given to the respective group of rabbits for 2 h after the bolus injection of heparin; heparin (50 U/kg/h, UFH-group), DX-9065a (0.05 mg/kg/h, DX-group) and argatroban (32 microG/kg/h, MD-group). During a 5-h observation period, the anti-Xa activity in circulating blood between the UFH- and DX-group and the anti-thrombin activity between the UFH- and MD-group were not significantly different. The graft patency in the DX-group (4/4) and MD-group (4/4) was significantly better than that in the UFH-group (3/10). Ultrastructural analysis of the luminal surface of the harvested graft by scanning electron microscopy revealed the reduced formation of fibrin networks entrapping erythrocytes in the DX- and MD-group in comparison with the patent UFH-group. In conclusion, a novel synthetic Xa inhibitor DX-9065a exerts a potent in vivo antithrombotic effect, which was comparable with argatroban, a synthetic thrombin inhibitor.
Introduction
Vein graft occlusion remains a significant clinical challenge in vascular surgery. Synthetic materials used in bypass procedures often trigger a robust coagulation cascade, leading to early graft failure. While unfractionated heparin (UFH) has long been the standard anticoagulant, its efficacy is often limited by neutralization from platelet-released factors (such as Platelet Factor 4) and the requirement of antithrombin III as a cofactor. This study investigates DX-9065a, a small-molecule synthetic Factor Xa inhibitor, as a more targeted alternative for preventing acute graft thrombosis.
Methods
The researchers utilized a highly thrombogenic rabbit model, replacing a 1cm segment of the inferior vena cava with a 3cm woven Tetron tube graft. Twenty-two male Japanese albino rabbits were assigned to four treatment protocols:
- Control: Single bolus of heparin (50 U/kg).
- UFH Group: Continuous infusion of heparin (50 U/kg/h).
- DX Group: Continuous infusion of DX-9065a (0.05 mg/kg/h).
- MD Group: Continuous infusion of Argatroban (32 µg/kg/h), a direct thrombin inhibitor.
Graft patency was monitored for 5 hours post-implantation using ultrasonic Doppler flow meters. Systemic anticoagulation was assessed via ex vivo assays, including activated partial thromboplastin time (aPTT) and anti-Xa activity. Luminal surfaces were examined using Scanning Electron Microscopy (SEM) to evaluate microscopic thrombus structure.
Results and Discussion
Coagulation Profiles
A critical finding was the divergence in systemic effects between UFH and DX-9065a. While both groups maintained similar levels of anti-Xa activity, the UFH group exhibited a massive prolongation of aPTT, reaching over 500% of baseline. In contrast, the DX group showed a much more modest increase in aPTT, suggesting a more localized or specific antithrombotic effect that avoids extreme systemic disruption of the coagulation profile.
Graft Patency and Thrombus Formation
The synthetic inhibitors significantly outperformed heparin. Both the DX and MD groups achieved 100% patency (4/4 each), whereas the UFH group had a failure rate of 70%, with only 3 out of 10 grafts remaining patent. Thrombus weights were also significantly lower in the synthetic inhibitor groups (DX: 22.8 mg; MD: 27.0 mg) compared to the UFH group (ranging from 42.6 to 60.3 mg).
Microscopic Evidence
Scanning electron microscopy (SEM) provided visual confirmation of these results. Grafts from the UFH group were characterized by dense fibrin networks and trapped erythrocytes. Conversely, grafts treated with DX-9065a or Argatroban showed minimal fibrin deposition, with only thin layers of platelet aggregates visible on the luminal surface. This suggests that DX-9065a effectively prevents the formation of the stable fibrin mesh required for occlusive thrombus growth.
Conclusion
DX-9065a demonstrates potent antithrombotic activity in a high-risk venous graft model, matching the efficacy of direct thrombin inhibitors like Argatroban. Its ability to maintain graft patency without the extreme systemic aPTT prolongation seen with heparin suggests a superior safety and efficacy profile for acute surgical applications. These findings highlighted the potential of small-molecule inhibitors, which eventually led to the development of modern direct oral anticoagulants (DOACs) used in clinical practice today.
Summary updated